- Home
- NUW vs IVVD Comparison
NUW vs IVVD Comparison
Compare NUW & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUW | IVVD |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.7M | 201.9M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NUW | IVVD |
|---|---|---|
| Price | $14.06 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 40.9K | ★ 3.0M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | N/A | $61.57 |
| Revenue Next Year | N/A | $41.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $13.50 | $0.49 |
| 52 Week High | $14.70 | $3.07 |
Technical Indicators
Market Signals| Indicator | NUW | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 50.83 |
| Support Level | $13.83 | $0.53 |
| Resistance Level | $14.10 | $1.01 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 92.00 | 82.61 |
Price Performance
Historical ComparisonAbout NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.
About IVVD Invivyd Inc.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.